down arrow

Solid Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US83422E2046
USD
5.92
0.82 (16.08%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.365.97

52 Week

2.417.37
Valuation
Technical
Day's Volume

CASH

1.64 M

Shareholding (Mar 2025)

FII

5.94%

Held by 43 FIIs

DII

51.05%

Held by 21 DIIs

Promoter

30.58%

How big is Solid Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Solid Biosciences, Inc. has a market capitalization of 357.35 million, with net sales of 0.00 million and a net profit of -139.68 million over the latest four quarters. The company reported shareholder's funds of 137.25 million and total assets of 188.66 million as of Dec 24.

Market Cap: As of Jun 18, Solid Biosciences, Inc. has a market capitalization of 357.35 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Solid Biosciences, Inc. reported net sales of 0.00 million and a net profit of -139.68 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 137.25 million and total assets of 188.66 million.

Read More

What does Solid Biosciences, Inc. do?

22-Jun-2025

Solid Biosciences, Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD). It has a market cap of $357.35 million and reported a net profit loss of $39 million as of March 2025.

Overview: <BR>Solid Biosciences, Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD) within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -39 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 357.35 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.03 <BR>Return on Equity: -45.26% <BR>Price to Book: 1.21<BR><BR>Contact Details: <BR>Address: 141 Portland St Fl 5, CAMBRIDGE MA: 02139-1937 <BR>Tel: 1 617 3374680 <BR>Fax: 1 302 6555049 <BR>Website: https://www.solidbio.com/

Read More

Who are in the management team of Solid Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Solid Biosciences, Inc. includes Ian Smith (Chairman), Ilan Ganot (CEO), and several independent directors: Matthew Arnold, Martin Freed, Robert Huffines, Adam Koppel, and Sukumar Nagendran.

As of March 2022, the management team of Solid Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. Ian Smith, Chairman of the Board<BR>- Mr. Ilan Ganot, President, Chief Executive Officer, Co-Founder, and Director<BR>- Mr. Matthew Arnold, Independent Director<BR>- Dr. Martin Freed, Independent Director<BR>- Mr. Robert Huffines, Independent Director<BR>- Dr. Adam Koppel, Independent Director<BR>- Dr. Sukumar Nagendran, Independent Director

Read More

Is Solid Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of August 14, 2023, Solid Biosciences, Inc. is considered overvalued with a valuation grade of "does not qualify," a Price to Book Value of 1.20, a troubling ROE of -45.26%, and a 1-year stock return of -30.19%, significantly underperforming compared to its peers and the S&P 500.

As of 14 August 2023, the valuation grade for Solid Biosciences, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, given its negative financial metrics. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 1.20. Notably, the ROE is a concerning -45.26%, reflecting substantial losses relative to equity.<BR><BR>In comparison to its peers, Solid Biosciences, Inc. has a valuation of -2.6812, while Instil Bio, Inc. is at -3.7811 and Nkarta, Inc. is at -1.1544. These figures suggest that Solid Biosciences is underperforming relative to its industry counterparts. Additionally, the company's recent stock performance shows a 1-year return of -30.19%, contrasting sharply with the S&P 500's 10.26% return over the same period, further reinforcing the notion that it is overvalued in the current market environment.

Read More

Is Solid Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 4, 2025, Solid Biosciences, Inc. shows a mildly bullish trend, supported by daily moving averages, despite mixed signals from weekly MACD and Dow Theory, with a short-term return of 2.45% compared to the S&P 500's 1.05%, but a long-term underperformance of -23.81% versus the S&P 500's 17.14%.

As of 4 August 2025, the technical trend for Solid Biosciences, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while weekly MACD and Dow Theory show mildly bearish signals. The Bollinger Bands are bullish on the weekly timeframe but bearish on the monthly. The stock has performed well in the short term with a 1-week return of 2.45% compared to the S&P 500's 1.05%, but it has underperformed over longer periods, with a 1-year return of -23.81% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 399 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.03

stock-summary
Return on Equity

-56.83%

stock-summary
Price to Book

1.55

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-39 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.96%
0%
2.96%
6 Months
69.14%
0%
69.14%
1 Year
14.29%
0%
14.29%
2 Years
96.68%
0%
96.68%
3 Years
-12.56%
0%
-12.56%
4 Years
-76.65%
0%
-76.65%
5 Years
-88.72%
0%
-88.72%

Solid Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Solid Biosciences, Inc. technically bullish or bearish?

As of 4 August 2025, the technical trend for Solid Biosciences, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while weekly MACD and Dow Theory show mildly bearish signals. The Bollinger Bands are bullish on the weekly timeframe but bearish on the monthly. The stock has performed well in the short term with a 1-week return of 2.45% compared to the S&P 500's 1.05%, but it has underperformed over longer periods, with a 1-year return of -23.81% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-12.27%
EBIT to Interest (avg)
-106.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.20
EV to EBIT
-0.34
EV to EBITDA
-0.34
EV to Capital Employed
-5.05
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-45.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 24 Schemes (12.43%)

Foreign Institutions

Held by 43 Foreign Institutions (5.94%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -0.51% vs 7.75% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.30",
          "val2": "-39.60",
          "chgp": "-4.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "-1.60",
          "chgp": "43.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.50",
          "val2": "-39.30",
          "chgp": "-0.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -29.90% vs -11.63% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-127.30",
          "val2": "-101.70",
          "chgp": "-25.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.70",
          "val2": "0.10",
          "chgp": "-4,800.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-124.70",
          "val2": "-96.00",
          "chgp": "-29.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-41.30
-39.60
-4.29%
Interest
0.10
0.10
Exceptional Items
-0.90
-1.60
43.75%
Consolidate Net Profit
-39.50
-39.30
-0.51%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -0.51% vs 7.75% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-127.30
-101.70
-25.17%
Interest
0.30
0.00
Exceptional Items
-4.70
0.10
-4,800.00%
Consolidate Net Profit
-124.70
-96.00
-29.90%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -29.90% vs -11.63% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Solid Biosciences, Inc. stock-summary
stock-summary
Solid Biosciences, Inc.
Pharmaceuticals & Biotechnology
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.
Company Coordinates stock-summary
Company Details
141 Portland St Fl 5 , CAMBRIDGE MA : 02139-1937
stock-summary
Tel: 1 617 33746801 617 3374680
stock-summary
https://www.solidbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."